Prilencapsule 25mg (Pregabalin)
Pregabalin 25mg
Hard capsule · Prescription medication
You & Life Sciences Co., Ltd.
MFDS item code 202001439 · Approved 2020.02.29
This product's status changed to Approval withdrawn on 2025.02.27. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of neuropathic pain, adjunctive treatment of epilepsy (partial seizures), and treatment of fibromyalgia
This drug is used to treat peripheral and central neuropathic pain in adults. It is also utilized as an adjunctive treatment for partial seizures in adults, whether or not accompanied by secondary general symptoms. Additionally, it is effective in alleviating symptoms of fibromyalgia, thus aiding in the treatment of various neurological disorders.
This medication is administered orally as pregabalin, in 2 divided doses per day, with or without food. Because this medication is primarily excreted by the kidneys, the dosage should be adjusted in patients with impaired renal function. (See section “5. Patients with Renal Impairment”) 1. Neuropathic pain 1) Peripheral neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central neuropathic pain Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section “4. Discontinuation of Treatment”) 2. Epilepsy Adults: This medication may be administered at an initial dose of 150 mg/day. Based on the individual patient's response and tolerability, the dose may be increased to 300 mg/day after 1 week. If necessary, it may subsequently be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this medication for fibromyalgia is 300 mg-450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day; however, there is no evidence of additional benefit or adequate tolerability at this dose. Considering the dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this medication is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this medication is primarily excreted by the kidneys as unchanged drug. Since the clearance of this medication is directly affected by creatinine clearance, dose reductions in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the formula below. Creatinine clearance (mL/min)* = [140 – age (years)] x body weight (kg) 72 x serum creatinine concentration (serum creatinine, mg/dL) * For women, multiply the result obtained using the above formula by 0.85. This medication is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1] Pregabalin dosage based on renal function Creatinine clearance (CLcr), (mL/min) Total daily dose of pregabalina Administration regimen Starting dose (mg/day) Maximum dose (mg/day) ≥60: Starting dose 150, maximum dose 600, BID or TID ≥30-<60: Starting dose 75, maximum dose 300, BID or TID ≥15-<30: Starting dose 25-50, maximum dose 150, QD or BID <15: Starting dose 25, maximum dose 75, QD Supplemental dose after hemodialysis: Starting dose 25, maximum dose 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be divided as indicated under the administration regimen. b: The supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dosage adjustment is necessary in patients with hepatic impairment. 8. Elderly patients (65 years of age or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Children under 12 years: Administration is not recommended because there are insufficient data on safety and efficacy. Adolescent patients aged 12-17 years: Administration is not recommended because there are insufficient data on safety and efficacy.
This drug may increase the risk of suicidal thoughts or behaviors, so changes in mood or symptoms of depression should be closely monitored during treatment. Patients with allergies to the components of this drug or those with specific genetic lactose degradation disorders should not take this drug. Diabetic patients may need to adjust the dosage of their blood glucose control medications due to potential weight gain after taking this drug. This drug can cause severe allergic reactions such as angioedema, so if swelling in the face or neck or difficulty breathing occurs, it should be discontinued immediately. Elderly patients may have an increased risk of falls due to dizziness or drowsiness when taking this drug, particularly during the initial dose. Temporary blurred vision or changes in vision may occur, and if symptoms persist, a consultation with a physician is advised. Withdrawal symptoms such as insomnia, headaches, and anxiety may occur upon discontinuation of this drug, so the dosage should be gradually reduced according to the physician's instructions. This drug has a risk of abuse, so patients with a history of substance abuse should take it with greater caution and notify their physician if any unusual behavior occurs. Patients with impaired kidney function may require dosage adjustment. Patients with heart disease or congestive heart failure should exercise caution while taking this drug. The risk of central nervous system depression may increase when used in combination with opioid analgesics, so a physician should be consulted. This drug may cause dizziness and drowsiness, so driving or operating hazardous machinery should be avoided after taking it. During early pregnancy, it may affect the fetus, so pregnant women are advised not to take it, and women of childbearing age should use effective contraception. Lactating women should consult with their physician regarding discontinuing breastfeeding or the drug, as this drug may be transmitted through breast milk. In the case of an overdose, symptoms such as confusion, drowsiness, and seizures may appear, necessitating an immediate visit to a medical institution. It should be kept out of reach of children and not transferred to other containers for safety. This drug has minimal drug interactions, but caution should be exercised when taken with other central nervous system depressants.
Not everyone experiences these, and they can vary from person to person.
This drug may be sensitive to air or moisture, so it should be stored in a tightly sealed container. It is important to maintain a storage temperature between 15 to 30 degrees Celsius.
A hard capsule with pale yellow upper part and white lower part containing white powder
30 capsules/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Pregabalin 25mg
Hard capsule · Prescription medication
You & Life Sciences Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 300mg
Hard capsule · Prescription medication
Viatris Korea Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Pregabalin 75mg
Hard capsule · Prescription medication
Hanmi Pharm. Co., Ltd.

Pregabalin 150mg
Hard capsule · Prescription medication
Hanmi Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.